TCF4 and urinary bladder carcinoma: In bladder cancer cells LY294002, a PI3K inhibitor, inhibits phosphorylation of AKT and GSK3β, and ZEB1 expression due to inhibition of β-catenin/transcription factor 4 (TCF4) complex binding and transcriptional activity on ZEB1 promoter [26].